MOMENTA PHARMACEUTICALS INC
MNTA evidence brief
What we can confirm
- BioSniper Score:
- 9.0 / 10
- Lead Asset:
- m230 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for MNTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
m230 (Phase 1)
Next Catalyst
—
Tracking 5 pipeline candidates · 6 clinical trials for MOMENTA PHARMACEUTICALS INC.
Run MOMENTA PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MOMENTA PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: BLA Filed
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is MOMENTA PHARMACEUTICALS INC's lead drug candidate?
MOMENTA PHARMACEUTICALS INC's most advanced tracked candidate is m230 (Phase 1) for autoimmune diseases.
Who is the CEO of MOMENTA PHARMACEUTICALS INC?
Craig A. Wheeler is the chief executive officer of MOMENTA PHARMACEUTICALS INC (MNTA).
What therapeutic areas does MOMENTA PHARMACEUTICALS INC focus on?
MOMENTA PHARMACEUTICALS INC develops therapies across Neurology, Immunology, Ophthalmology, Hematology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.